ArticleCureus2025
Epidemiological Study of Lactose- and Non-lactose-Fermenting Gram-Negative Bacterial Isolates From Clinical Specimens in the Middle Al-Furat Region of Iraq.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study included a collection of 682 clinical samples from the hospital laboratories all over Iraq's Middle Euphrates region, which encompasses the governorates of Najaf, Karbala, Babylon, and Diwaniyah. The study lasted for seven months, from April 2022 to the end of October 2022, and aimed to isolate and diagnose Gram-negative lactose-fermentative bacterial species while determining the extent of multidrug resistance (MDR) of the isolated bacteria to antibiotics.
methodSwabs were quickly taken to the lab in a special solution and placed on different types of growth media, like blood agar, nutrition agar, and MacConkey agar, and then the Vitek Compact 2 system was also used to confirm the identification of the bacteria. Susceptibility to antimicrobials was assessed according to the CLSI guideline.
resultsSix hundred and eighty-two Gram-negative bacterial isolates revealed that 468 (68.6%) were lactose-fermenting species, including E. coli (47.7%, 325/682), Klebsiella pneumoniae (13.9%, 95/682), and Enterobacter cloacae (7.0%, 48/682), while 214 (31.4%) were non-lactose-fermenters, predominantly Pseudomonas aeruginosa (10.6%, 72/682), Acinetobacter baumannii (8.5%, 58/682), Salmonella typhi (8.9%, 61/682), and Proteus mirabilis (3.4%, 23/682). Antibiotic susceptibility testing showed the highest efficacy for ampicillin (84.2%) and amoxicillin/clavulanic acid (75.5%), followed by cefotaxime (75.5%), ceftazidime (71%), imipenem (58.4%), and meropenem (63.8%), with all isolates exhibiting significant resistance (p < 0.0001) Conclusion: This work emphasizes the place of the Gram-negative bacteria as nosocomial and community-acquired pathogens. The rates of resistance are in accordance with a public health problem in the Middle Euphrates region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.